Screening for Barrett’s esophagus in asymptomatic women - 23/08/11
Stanford, California, USA
Abstract |
Background |
Barrett’s esophagus (BE) has been detected in approximately 10% of patients with chronic GERD. Previous studies demonstrated a similar prevalence of BE in asymptomatic adults.
Objective |
To determine the prevalence of BE in asymptomatic women.
Design |
We invited women scheduled for routine screening colonoscopy (for colorectal cancer) and women undergoing endoscopic examination before bariatric surgery to participate. Patients experiencing heartburn symptoms more than once per month were excluded.
Setting |
Outpatients at Stanford University and Palo Alto VA Health Care System.
Interventions |
Biopsies of the esophagogastric junction in the setting of suspected BE, and completion of symptom and health-related quality of life questionnaires to ensure that subjects were asymptomatic.
Main Outcome Measurement |
Identification of BE.
Results |
We detected BE in 8 (6%) of 126 subjects, including 3 (5%) of 61 of the women in the colorectal cancer screening cohort and 5 (8%) of 65 of the women in the pre–bariatric surgery cohort, all of whom had BE measuring 2 cm or less (P = .30). Patients found to have BE were more likely to be older (mean age 60 years vs 49 years, respectively; P = .04), but there was no difference in mean body mass index, ethnicity, or tobacco or alcohol use between patients with and without BE. BE was only present in pre–bariatric surgery subjects younger than the age of 50 and was most common in the 61- to 70-year age cohort in both groups. Erosive esophagitis, microscopic reflux changes, and Helicobacter pylori infection were not more common in the pre–bariatric surgery group.
Limitation |
Small number of subjects with BE detected.
Conclusions |
Short-segment BE was detected in 6% of asymptomatic women undergoing screening endoscopic examinations.
El texto completo de este artículo está disponible en PDF.Abbreviations : BE, BMI, CRC, EGJ, RSS
Esquema
DISCLOSURE: The following author disclosed financial relationships relevant to this publication: L. B. Gerson: speaker for AstraZeneca, Takeda Pharmaceuticals, and Santarus. Supported by a grant from the Estelle Buel Simon Fund at Stanford University and an American Gastroenterological Association Research Scholar Award to L. B. Gerson. The other author disclosed no financial relationships relevant to this publication. |
Vol 70 - N° 5
P. 867-873 - novembre 2009 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?